Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2016

View Archived Issues

Lilly presents efficacy and safety analyses of ixekizumab for moderate-to-severe psoriasis

Novel model systems developed for adenoid cystic carcinoma of the salivary gland

Biofrontera presents full phase III results of BF-200 ALA for the treatment of BCC

Novel antifungal compound VL-2397 enters phase I trials

Cancer Genetics launches next-generation sequencing panel for solid tumors

Dana-Farber Cancer Institute and University of Pennsylvania disclose HIV entry inhibitors

Corbus to study Resunab for systemic lupus erythematosus

d-Methadone safe and well tolerated in phase I chronic pain trial

Summit Therapeutics reports microbiome data from phase II trial of ridinilazole

Enrollment opens in phase I study of ISC-hpNSC for Parkinson's disease

Celldex to discontinue phase III study of Rintega following DSMB recommendation

Serum VEGF shows promise as a prognostic marker for pemphigus foliaceus

Efficacy of CCR4 antagonist from AstraZeneca tested in canine model of atopic dermatitis

Xencor initiates phase II trials of XmAb-5871 for IgG4-related disease and SLE

Update on progress of SORAMIC liver cancer study

Cempra to receive funding for phase II/III trial of solithromycin in pediatric patients with CABP

AbbVie and Boehringer Ingelheim enter global collaboration on immunology compounds

KemPharm files IND for KP-511

One-year data from phase III trial of Cx-601 for complex perianal fistulas in Crohn's disease

Plexxikon initiates phase Ib study of PLX-51107 in advanced malignancies

ITM raises funding to advance development of radiopharmaceutical products

Companies update initiatives in light of Zika virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...